Grants for Small businesses - Science and Technology

The "Privacy-Preserving Data Sharing in Practice" grant aims to fund research and development projects that create practical, scalable technologies for sharing data in a way that preserves privacy, with a focus on advancing privacy-enhancing technologies for artificial intelligence, developing tools and testbeds for safe data sharing, and promoting the usability and inclusiveness of these solutions.

The Academy of Kidney Cancer Investigators (AKCI) is a unique, interactive virtual academy that provides, intensive mentoring, national networking, and a peer group for scientist and clinician junior faculty. The KCRP created the Academy of Kidney Cancer Investigators in FY19 to align with several program priorities, which include to build research capacity in kidney cancer; increase collaborations to advance kidney cancer research, and support innovative research conducted by the next generation of kidney cancer scientists and clinicians. The overarching goal of the AKCI is to increase research capacity in kidney cancer through the development of successful, highly productive kidney cancer researchers in a collaborative research and training environment. The AKCI is a virtual career development and research training platform that currently consists of 11 Early-Career Scholars (ECS)/Designated Mentor pairs from different institutions, and one Academy Director. It is expected that six Early-Career Scholars will graduate by the fall of 2025 and four FY23 AKCI Early-Career Scholars/Designated Mentor awards will be made by September 2024. In addition, Academy graduates will continue to participate in the annual Academy meetings. Information about the Academy is available on the KCRP webpage and in the Kidney Cancer Program Booklet at https://cdmrp.health.mil/kcrp. The AKCI leadership team will identify opportunities for engagement with KCRP AKCI Scholars-Designated Mentors and KCRP FY25 (and subsequent year awardees) Postdoctoral and Clinical Fellowship Awardees. The Academy Director and Deputy Director catalyze the growth and professional development of the Early-Career Scholars in collaboration with their Designated Mentors, assess the progress of the ECSs, and facilitate communication and collaboration among all of the Academy members. The AKCI leadership team will also identify and offer opportunities for engagement (e.g., invitations to seminar series and in-person meetings) with FY24 Postdoctoral and Clinical Fellowship Awardees with FY24 KCRP AKCI-ECS-Designated Mentors (and subsequent year awardees). This FY24 funding opportunity is soliciting applications for an Academy Director (Principal Investigator [PI]) and Deputy Director (Partnering PI) to lead the AKCI. The newly selected FY24 Academy Director and Deputy Director will initiate their responsibilities no later than October 2025. The Academy Director and Deputy Director (hereafter referred to as Academy Leadership) must be established kidney cancer researchers and can be at different institutions. The Academy Leadership must demonstrate a strong record of mentoring and training early career investigators, a commitment to leadership, the ability to articulate methods toward research collaborations, and the ability to objectively assess the progress of all Scholars with their Designated Mentors in the AKCI. Other objectives will include execution of research that will engage AKCI FY24 Scholars (including subsequent-year Scholars), develop tools for Scholars to enable success, and provide opportunities to broaden their knowledge in kidney and renal pelvis cancers. The leadership team will identify and offer occasion(s) for the AKCI to network with KCRP FY24 Postdoctoral and Clinical Fellowship Awardees (and subsequent year awardees). Designated Mentors on FY24 KCRP AKCI Early-Career Scholar Award applications and Designated Mentors on open FY19 through FY23 KCRP AKCI Early-Career Scholar Awards (with the exception of those graduating in 2024) are not eligible to apply for this award. Note: An invited oral presentation is a requirement for application review of the KCRP AKCI LA, as described in Section II.D.2.b.iv, Additional Application Components. Responsibilities of the Academy Leadership include, but are not limited to: Act as a resource for all Scholars and Designated Mentors in the Academy over the Scholars 4-year period of performance. Facilitate communication and collaboration among all Scholars and Designated Mentors (including periodic interactive communication among all Academy members). Develop assessment criteria to evaluate the research progress made by all Scholars, as well as their career progression and sustainment as independent investigators in kidney cancer research. Conduct collaborative kidney cancer pilot project(s) that include Academy Scholars. These pilot projects should have the potential to improve collaboration within the Academy, as well as impact kidney cancer research and/or kidney cancer patients/survivors. o Examples of pilot research projects may include but are not limited to (a) funding an extended statistical or bioinformatics analysis with AKCI Scholars, (b) performing a large-scale meta-analysis of human or animal datasets with AKCI scholars, (c) provide access to critical biorepositories or animal models to expand AKCI investigator analyses or increase study rigor. Provide constructive critiques with the goal of advancing the research and professional careers of the Scholars and strengthening the mentorship of the Designated Mentors. Provide avenues to increase the promotion of the Academy and visibility of Scholars within kidney cancer research and advocacy communities (e.g., peer review, conferences, editorial boards). Support the professional development, to include laboratory management skills, of the Scholars into leading researchers through invited presentations by experts outside of the AKCI LA. Plan and host an annual 1-day workshop and, biennially, a multi-day workshop for all Scholars/Designated Mentor pairs as well as Academy graduates to present their research, share knowledge, and develop collaborative efforts within the AKCI. Scholars will be responsible for their own travel costs to in-person Academy meetings. Include KCRP FY24 Postdoctoral and Clinical Fellowship Awardees in at least one meeting of the FY24 AKCI. These investigators will be responsible for their own travel costs, funds for which are included in their research awards. Establish a panel of patient advocates and Veteran(s) (i.e., the Patient Advocacy Panel) to inform the AKCI on the needs of the patient community. Establish the Designated Mentor Panel to facilitate collaborations among the AKCI participants including the Scholars, Academy Director/Deputy Director, and the Designated Mentors. The Academy of Kidney Cancer Investigators Leadership Award is structured to support two PIs. The Academy Director will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The Deputy Director will be identified as the Partnering PI. The collaboration between the Academy Director and the Deputy Director should be supported by complementary expertise and experience. Initiating and Partnering PIs each have different submission requirements, as described in Section II.D.2, Content and Form of the Application Submission; however, both PIs should contribute significantly to the development of the proposed research project. The application should clearly demonstrate that both PIs have equal levels of input on the proposed Academy Leadership and clearly define the components to be addressed by each to support the success of the Scholars. While it is up to the Academy Director and the Deputy Director to define their roles, both Academy Leaders should have interactions with each Scholar-Designated Mentor pair, (and the Scholars Designated Mentors); acting as administrative support does not fulfill the intent of the Director and Deputy Director. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PI(s), refer to Section II.D.2, Content and Form of the Application Submission. Organizational-Level Emphasis: The following areas of emphasis are broadly applicable to many CDMRP programs, not just the KCRP. Investigators are encouraged to consider addressing these areas in their applications if doing so is appropriate for their line of research, addresses the FY24 KCRP strategic priorities and/focus areas described in Section II.A.1 and Section II.A.2. Nuclear Medicine: Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies. Womens Health: CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in womens health outcomes and/or advancing knowledge for womens health. Metastatic Cancer Task Force: A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 KCRP priorities. Rigorous Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies. Military Service Involvement: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Clinical trials are not allowed under this funding opportunity. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes: (1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule. The funding instrument for awards made under the program announcement will be cooperative agreements (31 USC 6305). Substantial CDMRP programmatic involvement with recipients is anticipated during the performance of award activities. Substantial involvement means that, after award, CDMRP staff will assist, guide, coordinate, or participate in project activities including but not limited to: Participating in the Steering Committee that oversees study conduct. Make recommendations for continued funding based on (a) overall study progress, including sufficient patient and/or data accrual; (b) cooperation in carrying out the research (e.g., attendance at Steering Committee meetings, implementation of group decisions, compliance with the terms of award and reporting requirements); and/or (c) maintenance of a high quality of research. The anticipated combined direct costs budgeted for the entire period of performance for a FY24 KCRP AKCI LA should not exceed $1,500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. Awards supported with FY24 funds will be made no later than September 30, 2025. The CDMRP expects to allot approximately $2.4M to fund approximately one KCRP Academy of Kidney Cancer Investigator Leadership Award application (consisting of an Initiating PI application and a Partnering PI application). Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 and FY26 funds, which will expire for use on September 30, 2030, and September 30, 2032, respectively.

The IDEA Fund program is a state-sponsored venture capital initiative that utilizes public funding (both state and federal) to drive economic development within the state. The primary focus of this program is to foster innovation and support technology-driven entrepreneurial endeavors that contribute to the state’s overall economic development growth. MTC’s Venture Capital Program was created to accelerate private venture capital investment in Missouri-based start-up companies and to increase the overall investment impact of third-party investments. The Venture Capital Program supports technology startups through matching equity or convertible debt investments up to $2,000,000 for the purpose of scaling the business to attract additional venture capital. Since 2010, MTC has invested over $49 million in more than 150 early-stage Missouri-based high-growth technology-focused companies. Since 2018, our portfolio companies have gone on to raise over $1.6 billion in additional private capital.

This funding opportunity provides financial support to Massachusetts-based organizations that help early-stage climatetech startups grow and innovate, covering various operational and developmental expenses.

The Program supports research on the sources, sinks, transport, and transformation of gases and aerosols in the atmosphere through models, observations, and experiments, including homogeneous and heterogeneous chemical reactions, emissions, deposition, atmospheric oxidation and photochemistry, aqueous-phase chemistry and aerosol processes; the formation of new particles and secondary organic aerosols, the modeling of atmospheric chemical processes, the study of chemical mechanisms in the atmosphere, optical properties of gases and aerosols, and improved methods for measuring the concentrations of trace species and their fluxes into and out of the atmosphere.The Program encourages principal investigators from a wide variety of institutions and backgrounds to submit proposals.

Main Street Ventures offers Launch Funding to emerging, pre-revenue businesses that have a prototype or product. This grant program aims to support the growth and scaling of businesses within the Greater Cincinnati region, aligning with the foundation's mission to foster economic development and innovation in the area. The funding is specifically designed to cover key direct costs associated with growth projects, rather than general operating expenses, reflecting a strategic priority to provide tangible support for business acceleration. The primary target beneficiaries are business entities (C-Corp, S-Corp, or LLC) with a Federal Tax ID (EIN) located in the Greater Cincinnati region, which includes specific counties in Ohio, Kentucky, and Indiana. Businesses must demonstrate customer demand and strong progression since their founding. The program focuses on specific growth projects that will accelerate business growth, with examples of suitable direct expenses including key equipment, packaging support, and technology product development. This targeted approach ensures that the grant funds directly contribute to measurable business expansion. Special consideration is given to women and minority-owned businesses, as well as businesses that can show matching funds from other sources. This reflects the foundation's strategic priorities to promote inclusivity and leverage additional investment, thereby maximizing the overall impact on the regional economy. The expected outcomes include the scaling of businesses, job creation, and increased economic vitality within the Greater Cincinnati region, with successful applicants demonstrating a clear impact of the grant funds on their business or the region. The Main Street Ventures' theory of change is rooted in providing early-stage, direct financial assistance to promising businesses to help them overcome critical growth hurdles. By focusing on direct costs and specific growth projects, the program aims to create a ripple effect, enabling these businesses to achieve significant milestones that would otherwise be out of reach. The emphasis on local businesses and underrepresented founders further amplifies the foundation's commitment to building a robust and equitable entrepreneurial ecosystem in the Greater Cincinnati area. The grant duration of three years allows for sustained support and monitoring of the businesses' progress.

This funding opportunity supports innovative research on rare cancers, providing up to $490,000 for early-stage projects that aim to improve diagnosis, understanding, and treatment, particularly benefiting military service members, veterans, and the general public.

The Arizona Department of Veterans' Services (ADVS) provides critical, statewide coordination and technical assistance to services and organizations serving Veterans. This includes activities such as the Arizona Veteran StandDown Alliance, and outreach events that support homeless and at-risk military Veterans in Cochise, Coconino, Gila, Graham/Greenlee, La Paz, Maricopa, Mohave, Navajo, Pima, Pinal, Yavapai, and Yuma Counties. Financial Notes: Total Funding for this grant is $303,000

The OCRP seeks to advance ovarian cancer research through development of early-career investigators. The OCRP Ovarian Cancer Academy (OCA) is a unique, interactive environment providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty to move ovarian cancer research into a new frontier. The overarching goal of the OCA is to develop successful, highly productive ovarian cancer researchers in a collaborative research and career development environment to enhance quality and expand quantity of the ovarian cancer research field.

The FY24 KCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, it allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not allowed and should not be discussed. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of kidney cancer or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.Organizational-Level Emphasis Areas:The following areas of emphasis are broadly applicable to many CDMRP programs, not just the KCRP. Investigators are encouraged to consider addressing these areas in their applications if doing so is appropriate for their line of research, addresses the FY24 KCRP strategic priorities and/or focus areas described in Section II.A.1 and Section II.A.2.Nuclear Medicine: Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.Womens Health: CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in womens health outcomes and/or advancing knowledge for womens health.Metastatic Cancer Task Force: A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 KCRP priorities.Rigorous Study Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (https://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Military Service Involvement: Applications from investigators within the military services and applications involving multidisciplinary collaborations among academia, industry, the military services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s). Refer to Section II.D.2.b.i, Full Application Guidelines, for more information.Clinical trials are not allowed under this funding opportunity.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 KCRP Concept Award should not exceed $100,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $1.44M to fund approximately nine Concept Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This grant provides funding for researchers and organizations to conduct studies and develop technologies related to the workings of the solar system, supporting a wide range of scientific investigations in planetary science.

The SCIRP TRA is intended to support translational research that will accelerate the movement of promising ideas in SCI research into clinical applications. Although not all-inclusive, some examples include demonstration studies of pharmaceuticals and medical devices in preclinical systems and/or clinical research on therapeutics, devices, or practice using human tissues or resources.The ultimate goal of translational research is to move an observation forward into clinical application and accelerate the clinical introduction of health care products, technologies, or practice guidelines. Observations that drive a research idea may be derived from a laboratory discovery, population-based studies, or a clinicians first-hand knowledge of patients and anecdotal data. However, applicants should not view translational research as a one-way continuum from bench to bedside. The research plan is encouraged to involve a reciprocal flow of ideas and information between basic and clinical science.

This initiative provides funding to defense contractors and formal methods developers to enhance cybersecurity in military software systems by integrating advanced verification tools.

This program provides financial support to New Mexico-based small businesses with federal SBIR or STTR grants, helping them commercialize innovative technologies and grow their market presence.

The Alexander County Economic Development Corporation is offering grants of $1,000 to $5,000, funded by the Duke Energy Foundation, to businesses in Alexander County, North Carolina, for projects aimed at enhancing physical spaces, e-commerce, service delivery, equipment purchase, ADA accessibility, and public health compliance, with a special focus on fostering entrepreneurship and expanding childcare centers.

The purpose of this document is to advise the public that the NOAA RESTORE Science Program is soliciting proposals for projects of five years in duration with the option for a five year, non-competitive renewal award for high-performing projects. This announcement invites proposals that request funding for partnerships that include researchers, resource managers, and other interested parties to conduct a collaborative research project that will identify, track, understand, or predict trends and variability in the Gulf of Mexicos natural resources and the abiotic and biotic factors driving those trends. Funding is contingent upon the availability of funds in the Gulf Coast Restoration Trust Fund. It is anticipated that final recommendations for funding under this Announcement will be made in June 2025, and that projects funded under this Announcement will have a October 1, 2025 start date. Total funding for this competition will be approximately $17.5 million over five years and approximately six projects may be funded. The minimum individual award amount is approximately $1 million over five years (an average of $200,000 per year) and the maximum individual award amount is approximately $4 million over five years (an average of $800,000 per year). An additional $21 million may be available for five year, non-competitive renewals for high performing projects. Information regarding this Announcement, including webinars and additional background information, is available on the Science Programs website (https://restoreactscienceprogram.noaa.gov/funding-opportunities/ffo-2025).The NOAA RESTORE Science Program encourages applicants and awardees to support the principles of diversity, equity, and inclusion when writing their proposals and performing their work. Promoting diversity, inclusion, and equity improves the creativity, productivity, and vitality of the research and management communities and leads to more robust natural resource management decisions.Electronic Access: The NOAA RESTORE Science Program website (http://restoreactscienceprogram.noaa.gov/) furnishes supplementary information. Full proposals should be submitted electronically through Grants.gov (http://www.grants.gov).

This program provides funding to various organizations to expand high-speed internet access in underserved areas of Illinois, focusing on improving connectivity for schools, libraries, and health facilities.

This initiative provides financial and technical support to small businesses in Detroit that have been operating for 30 years or more, recognizing their cultural and economic contributions to the community.

The Northwestern STEM Network Grant VI, administered by the Nevada Governor’s Office of Science, Innovation, and Technology (OSIT), aims to support innovative initiatives that align with the objective of developing a diverse talent pool to meet the employment needs of Northwestern Nevada’s evolving STEM industries. Projects should address equity in STEM, raise awareness about STEM opportunities, and ensure high-quality STEM education with engaged business partners across all counties, cities, and districts. Funding is available up to $50,000, with applications due by June 28, 2024. Eligible projects include pilot programs, scaling up existing programs, or extending successful initiatives from other regions.

This funding opportunity provides financial support for small businesses to develop innovative technologies for harnessing geothermal energy from extremely hot rock formations, promoting sustainable electricity production.